{"links":{"html":"https://www.erudio.com/reports/pace-lung-nct05281406","json":"https://www.erudio.com/reports/pace-lung-nct05281406.json","markdown":"https://www.erudio.com/reports/pace-lung-nct05281406.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"pace-lung-05281406"}},"request":"https://www.erudio.com/contact?report=pace-lung-05281406"},"offer":{"cited_commentary_sources":16,"verified_hcp_statements":76,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":10,"optional":true,"price_per_verified_person_usd":15,"price_usd":150,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"pace-lung-nct05281406"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=pace-lung-05281406","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/pace-lung-nct05281406","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-28T22:43:36.304164Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":5,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Progression Free Survival (PFS1)"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":3,"title":"Secondary endpoints"},{"claim_count":4,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":11,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":9,"title":"The comparison"},{"claim_count":4,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":1,"title":"Safety and tolerability"},{"claim_count":10,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":11,"coverage":"discussed","id":"A1","source_count":7,"title":"Prognostic versus predictive value and chemotherapy sparing"},{"claim_count":5,"coverage":"discussed","id":"A2","source_count":5,"title":"Assessment timing, later clearance and co-mutations"},{"claim_count":9,"coverage":"discussed","id":"A3","source_count":1,"title":"Individual no-chemotherapy pathway and expectations of durability"},{"claim_count":11,"coverage":"discussed","id":"A4","source_count":1,"title":"Incidental BRCA2, add-on treatment ideas and genetics referral"},{"claim_count":12,"coverage":"discussed","id":"A5","source_count":1,"title":"Baseline assay detectability and conditional preference for noninvasive sampling"},{"claim_count":9,"coverage":"discussed","id":"A6","source_count":1,"title":"Monitoring burden, pleurodesis-related imaging uncertainty and adjunct use"},{"claim_count":6,"coverage":"discussed","id":"A7","source_count":3,"title":"Research interest and molecular-subtype reassurance"}],"counts":{"cited_sources":17,"claims_by_expression_type":{"comparison":4,"experience":11,"interpretation":20,"opinion":11,"primary_context":2,"question":4,"restatement":14,"uncertainty":5,"unspecified":5},"claims_by_kind":{"protocol_statement":2,"source_observation":74},"clinician_statements":14,"evidence_units":58,"findings":8,"people_cited":11,"people_identity_verified":10,"people_total":11,"screened_sources":30,"verified_claims":76},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":6},"has_counterview":false,"limitations":3,"links":{"context":7,"support":9},"ma_question":true,"named_voices":3,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"Prognostic information is not automatically a treatment-selection rule"},{"id":"F2","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":0,"views":1},"has_counterview":false,"limitations":3,"links":{"context":3,"support":5},"ma_question":true,"named_voices":2,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Chemotherapy sparing remains a question, with stronger and more cautious interpretations reported"},{"id":"F3","structure":{"claims":7,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":3,"views":2},"has_counterview":true,"limitations":3,"links":{"context":2,"support":10},"ma_question":true,"named_voices":5,"passages":7,"sources":7,"sources_by_kind":{"commentary":7}},"title":"Feasibility and favorable historical comparisons attracted interest, without settling comparative benefit"},{"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":2,"questions":2,"restated":3,"views":2},"has_counterview":false,"limitations":4,"links":{"context":2,"support":11},"ma_question":true,"named_voices":5,"passages":8,"sources":8,"sources_by_kind":{"commentary":5,"media":2,"registry":1}},"title":"The three-week trigger and molecular characterization are specific unresolved selection questions"},{"id":"F5","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":7},"has_counterview":false,"limitations":4,"links":{"context":2,"support":10},"ma_question":true,"named_voices":0,"passages":9,"sources":1,"sources_by_kind":{"media":1}},"title":"An individual early decline supported continuing Tagrisso without chemotherapy, with explicitly tentative expectations"},{"id":"F6","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":1,"questions":3,"restated":5,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":11},"ma_question":true,"named_voices":0,"passages":9,"sources":1,"sources_by_kind":{"media":1}},"title":"Incidental BRCA2 prompted treatment questions, but not an immediate PARP-inhibitor addition"},{"id":"F7","structure":{"claims":17,"claims_by_group":{"comparisons":1,"experience":3,"questions":0,"restated":5,"views":8},"has_counterview":false,"limitations":3,"links":{"context":3,"support":17},"ma_question":true,"named_voices":0,"passages":15,"sources":1,"sources_by_kind":{"media":1}},"title":"Blood-based testing was valued for access and reduced procedure burden, conditional on adequacy and reliability"},{"id":"F8","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":4,"questions":1,"restated":3,"views":3},"has_counterview":false,"limitations":3,"links":{"context":1,"support":12},"ma_question":true,"named_voices":0,"passages":11,"sources":1,"sources_by_kind":{"media":1}},"title":"Favorable tolerability coexisted with monitoring anxiety, imaging uncertainty and an unproven adjunct rationale"}],"medical_affairs_question":"What evidence would justify delaying or omitting upfront combination treatment, and which ctDNA time point and subgroup would support that choice?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Clearance describes prognosis, but does it select treatment?"},{"id":"section-2","level":2,"title":"Baseline-undetectable patients are a distinct chemotherapy-sparing question"},{"id":"section-3","level":2,"title":"Feasibility is encouraging, but the comparator and time origin matter"},{"id":"section-4","level":2,"title":"Why three weeks, and which persistent patients?"},{"id":"section-5","level":2,"title":"An individual no-chemotherapy pathway is not a validated de-escalation rule"},{"id":"section-6","level":2,"title":"Incidental BRCA2 required work-up before an additional targeted-treatment idea"},{"id":"section-7","level":2,"title":"Liquid biopsy was valued, but sufficiency and reliability remained conditions"},{"id":"section-8","level":2,"title":"Tolerability and reassurance did not remove monitoring or interpretation burdens"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2","trial_dimensions":[{"findings":[{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression Free Survival (PFS1)"},{"findings":[{"id":"F3","shared_claims":2}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F4","shared_claims":1},{"id":"F7","shared_claims":3}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":3}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":5},{"id":"F7","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-28T22:43:36.304164Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-28T23:06:15Z","record_hash":"2d9fccc722a506b8bac9f12883796ec085f479b9a26ef4cac67be4a88887054a","release_hash":"2337dba15a23cd206a1fd5268da634be1b10806155936482a141e7bb0ce01dc8","report_id":"erudio-nct05281406","run_id":"cdd0c29d-b613-484c-8344-c986b0126d9f","schema_version":"5.0","slug":"pace-lung-05281406","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"PACE-LUNG asks whether adding chemotherapy when tumor DNA persists in blood during first-line osimertinib improves outcomes in advanced EGFR-mutant NSCLC. Clinicians in the sources reviewed for this edition express interest in selective escalation while leaving comparative benefit unsettled. Feasibility attracts interest, while assessment timing and molecular characterization draw scrutiny. Patient selection remains open. These sources place the trial’s main results at ESMO 2026.","meta_description":"30 sources screened · 76 verified statements (14 from clinicians verified by NPI or staff page) from 17 sources · 8 findings. Updated Oct 28, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-23aa42a12d460033eccf","claim-87824fc2d49e47e481c1"],"id":"F4","paraphrase":"Posts on X asked about the timing of the ctDNA assessment used to select chemotherapy escalation and about co-mutations in patients selected for escalation.","publication_caveats":["The clinical roles of the authors asking these questions are not stated in the sources reviewed for this edition."],"source_channel":"x_thread","source_date":"2026-10-24","title":"The three-week trigger and molecular characterization are specific unresolved selection questions"}]},"publication":{"approved_at":"2026-10-28T23:06:15Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":30},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","45 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative survey of HCPs. Repeated posts and relays of the same discussion cannot be counted as independent agreement.","No full protocol or exact-trial results publication was available. Registry statements describe methods and hypotheses; reported outcomes come from commentary about presentations.","Discussions that do not name PACE-LUNG, or use different spellings, may be absent. Some relevant passages were not fully assessed, so the report is not a complete account of public discussion.","The podcast and preview speech cannot be assigned to named individuals. The podcast does not establish that its personal treatment accounts are HCP recommendations.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Reported PFS and OS estimates have different or incompletely specified time origins. Historical comparisons and presentation relays cannot establish comparative treatment benefit.","Baseline-undetectable patients and patients achieving clearance after starting treatment are different groups; favorable prognosis does not by itself establish that chemotherapy can safely be omitted.","Personal accounts do not provide aggregate adverse-event, comparative safety or trial quality-of-life results. The hyperthermia rationale is not demonstrated clinical benefit."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":1,"regulatory":0,"x_thread":13,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":16,"methods":1},"count":17,"evidence_window":{"end":"2026-10-28","start":"2023-05-29"},"retrieval_snapshot":"2026-10-28T22:03:07.638877Z","timeline":[{"count":1,"week":"2023-W22"},{"count":1,"week":"2024-W04"},{"count":1,"week":"2026-W08"},{"count":12,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05281406:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05281406:context","quote_policy":"short_quote_link_out"},{"id":"openfda:caef07ce-066b-4c48-98dc-974b05ebbbe0:20260618","quote_policy":"short_quote_link_out"},{"id":"openfda:508496cb-3441-46b3-a4fe-e0d440e6adc6:20260624","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:989e16","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1504104391812427777:c0ac0227-9586-4eb9-a343-a7ab846b65d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1557117896286908416:b9d93653-b862-4e2b-950b-2e94b8792452","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1569288938145316866:aa018595-1fa0-49b4-a289-5b8105ca0a51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1585591071387840513:24158366-fc92-4eeb-98c9-f5c77acd6edb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1750705439241892070:866b34a4-4a7c-4b4a-98a8-99b733d6b6b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2024889353537978591:6d9d1e2e-0e1c-4be1-b589-add4251de3e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103816863713267719:9f01d2cf-cb2a-42c0-ab1a-3e6bc3882d46","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107390688413339706:b17c3c31-43b8-41ec-b2a8-c07f203d5227","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109655085940977897:ad3cab0c-5bf9-452e-975d-305717280ded","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112178881478132160:963eda0e-5685-4324-b2bc-65df7e2cc6be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112867869759537359:41c5ee38-f46c-4e70-8695-11399f7c20ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113837855386542578:10f8be71-5187-47c1-a706-55767d45a9e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113860739425542648:e6134ff1-27bd-455e-82ee-f626880f3d88","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113882399797072074:84f117e4-bed6-44eb-8d8a-5cea3c358f34","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113882584367165877:cac6a024-2065-43b2-b2b0-1da515fb93e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113882673265467560:85bed5cb-13af-4302-84b0-7e7064ca3fc5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113882811157389401:3ba6f4a0-16d1-4d07-9a65-dcb8f2ddf330","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113882947963048267:7fca98b1-5c7d-4314-b062-78d2376247f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113884829930725618:8516db74-f7b9-48db-96b7-bd1dc90eba98","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113889557460509007:a2afc915-9d15-41f5-81a9-2be0a3000571","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113890135515283535:2ae8c463-360d-45c3-8760-1f757cfab006","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113890586487075141:632ca83a-74fc-4a8d-ac3d-548a880277c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113891581686133091:66fc5551-c3df-40f6-afe6-0237e8ef946d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113930118611574788:a9b7089a-6258-4f7b-bc48-7f3f5dc49bc0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113931600823996452:a7ec75ce-8682-4be7-8380-6c32d093882d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113939011509027069:cd8657a6-5c1d-4c8b-80c4-bab8759bd52d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113976992513036429:ef87b6a8-9ad4-401d-aec5-2b3550da34df","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ATOUnP-HY-g","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:oBmIZ_WFq6Y","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":27,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":30},"count":30,"evidence_window":{"end":"2026-10-28","start":"2022-03-16"},"retrieval_snapshot":"2026-10-28T22:03:07.638877Z","timeline":[{"count":1,"week":"2022-W11"},{"count":1,"week":"2022-W32"},{"count":1,"week":"2022-W37"},{"count":1,"week":"2022-W43"},{"count":1,"week":"2023-W22"},{"count":1,"week":"2024-W04"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":19,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Tagrisso"],"label":"osimertinib","slug":"osimertinib"},{"brand_names":["Alimta"],"label":"pemetrexed","slug":"pemetrexed"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"}],"indications":[{"reason":"Unmapped registry condition: NSCLC Stage IIIB","status":"unmapped"},{"reason":"Unmapped registry condition: NSCLC Stage IV","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"PACE-LUNG","aliases":["PACE-LUNG","Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)"],"brief_title":"Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["NSCLC Stage IIIB","NSCLC Stage IV"],"enrollment":{"count":50,"type":"ESTIMATED"},"interventions":[{"name":"Osimertinib","synonyms":["Tagrisso"],"type":"DRUG"},{"name":"Pemetrexed","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05281406","official_title":"Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)","overall_status":"RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2025-11","type":"ESTIMATED"},"primary_endpoints":[{"description":"Progression Free Survival using investigator assessments according to Response Evaluation Criteria in Solid Tumours (RECIST 1.1) defined as number of months from first dose of chemotherapy until last follow-up, PD, death or withdrawal of consent.","measure":"Progression Free Survival (PFS1)","timeFrame":"2 years"}],"registry_last_updated":"2025-02-21","registry_url":"https://clinicaltrials.gov/study/NCT05281406","short_name":"PACE-LUNG","short_name_basis":"canonical_name","sponsor":"Goethe University","start_date":{"date":"2021-11-12","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"PACE LUNG","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}